Abstract 190P
Background
The combination of gemcitabine and nab-paclitaxel (GnP) has been established as the first-line chemotherapy in patients (pts) with metastatic pancreatic cancer (M-PC). However, the efficacy of the therapy in pts with borderline resectable PC (BR-PC) and locally advanced PC (LA-PC) is not clear. Although achieving R0 resection is one of the main target for these pts, the details of the response, such as the best time to evaluate the response is not clear. Therefore, we evaluated the details of response with GnP treatment.
Methods
We retrospectively reviewed the medical records of pts with BR-PC, LA-PC, and M-PC who received GnP as the first-line chemotherapy between January 2016 and April 2019 at six hospitals. We investigated time to response (TTR), duration of response (DoR), and depth of response (DpR). The response of the primary tumor and the metastases were evaluated separately in pts with M-PC. The response of the primary tumor was evaluated in all pts.
Results
A total of 47 pts were analyzed; the median age was 70 years, male was 66% and the number of pts with BR-PC/LA-PC/M-PC was 6%/26%/68%. The response rates of primary tumor and metastases were 40% and 31%, respectively. Among the pts with M-PC, seven had a partial response (PR) of the primary tumor without PR of metastases. The median TTR and time to best response of the primary tumor and metastases were 3.17 months (m) and 4.21 m (p = 0.191), and 4.11 m and 5.88 m (p = 0.724), respectively. The median DoR of the primary tumor and metastases were 5.36 m and 4.11 m, respectively (p = 0.277). The median DpR of the primary tumor and metastases were 28.3% and 15.3%, respectively (p = 0.733). The median progression-free survival and overall survival in M-PC pts with and without PR of the primary tumor were 8.48 m and 6.41 m (p = 0.267), and 14.72 m and 7.66 m (p = 0.186), respectively.
Conclusions
The response of the primary tumor tended to be higher and earlier than that of the metastases. A favorable efficacy was observed in pts with BR-PC and LA-PC as well as pts with M-PC. This study indicated that the best time to evaluate the response of the primary site to consider the conversion therapy was around 4 m. Pts with M-PC showing PR of the primary tumor tended to have a favorable prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract